{"classes":[{"categories":[{"measurements":[{"comment":"Too few events occurred to estimate the median and confidence interval.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Progression-free survival is defined as the time from registration to the earliest date of documentation of disease progression or death due to any cause. Patients who receive subsequent treatment for myeloma before disease progression will be censored on the date of their last disease assessment prior to initiation of the subsequent treatment. Transplant will not be considered subsequent treatment. The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 25 mg lenalidomide PO daily on days 1-21 and 40 mg dexamethasone PO daily on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive 200 mg pembrolizumab IV over 30 minutes on days 1 and 22 of course 1, day 15 of course 2, and day 8 of course 3. Courses 1-3 repeat beyond 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo stem cell transplantation after 4 courses of treatment.","id":"OG000","title":"Treatment (Lenalidomide, Dexamethasone, Pembrolizumab)"}],"paramType":"MEDIAN","populationDescription":"All patients that began protocol treatment were included in this analysis.","reportingStatus":"POSTED","timeFrame":"From registration to the earliest date of documentation of disease progression or death due to any cause, assessed up to 3 years","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}